Absci Corp (NASDAQ:ABSI) — Market Cap & Net Worth
Market Cap & Net Worth: Absci Corp (ABSI)
Absci Corp (NASDAQ:ABSI) has a market capitalization of $345.85 Million ($345.85 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14374 globally and #3247 in its home market, demonstrating a 23.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Absci Corp's stock price $4.92 by its total outstanding shares 150371531 (150.37 Million). Analyse Absci Corp cash conversion from operations to see how efficiently the company converts income to cash.
Absci Corp Market Cap History: 2021 to 2026
Absci Corp's market capitalization history from 2021 to 2026. Data shows change from $1.23 Billion to $739.83 Million (-26.62% CAGR).
Index Memberships
Absci Corp is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #381 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1371 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.02% | #206 of 263 |
Weight: Absci Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Absci Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Absci Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
86.89x
Absci Corp's market cap is 86.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.23 Billion | $4.78 Million | -$100.96 Million | 257.85x | N/A |
| 2022 | $315.78 Million | $5.75 Million | -$104.90 Million | 54.95x | N/A |
| 2023 | $631.56 Million | $5.72 Million | -$110.57 Million | 110.45x | N/A |
| 2024 | $393.97 Million | $4.53 Million | -$103.11 Million | 86.89x | N/A |
Competitor Companies of ABSI by Market Capitalization
Companies near Absci Corp in the global market cap rankings as of May 2, 2026.
Key companies related to Absci Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Absci Corp Historical Marketcap From 2021 to 2026
Between 2021 and today, Absci Corp's market cap moved from $1.23 Billion to $ 739.83 Million, with a yearly change of -26.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $739.83 Million | +40.97% |
| 2025 | $524.80 Million | +33.21% |
| 2024 | $393.97 Million | -37.62% |
| 2023 | $631.56 Million | +100.00% |
| 2022 | $315.78 Million | -74.39% |
| 2021 | $1.23 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Absci Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $345.85 Million USD |
| MoneyControl | $345.85 Million USD |
| MarketWatch | $345.85 Million USD |
| marketcap.company | $345.85 Million USD |
| Reuters | $345.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Absci Corp
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treat… Read more